Four gene markers, BARD1 (BRCA-associated RING domain 1), SOD2 (superoxide dismutase 2), S100A10, and TSC22D3 (TSC22 domain family member 3), were found to be the targets of several approved cancer drugs. Here, S100A10 is linked to cancer.